AI in Drug Development
A section of Pharmaceuticals (ISSN 1424-8247).
Section Information
This section, Artificial Intelligence in Drug Development, is dedicated to the application of artificial intelligence (AI), machine learning (ML), and related computational approaches across all stages of drug discovery and development. Contributions may focus on the use of AI tools to enhance the prediction, design, evaluation, and optimization of drug candidates, as well as AI-driven strategies for understanding biological systems.
Manuscripts may include research that integrates AI with omics data, real-world evidence, or high-throughput screening technologies. Studies presenting novel AI algorithms, frameworks, or platforms with demonstrated pharmaceutical relevance are also within the scope of this section. Download Section FlyerKeywords
- artificial intelligence
- machine learning
- deep learning
- drug discovery and design
- virtual screening
- de novo drug design
- QSAR and predictive modeling
- computational pharmacology
Special Issues
Following special issues within this section are currently open for submissions:
- Allosteric Drug Design in the AI Era (Deadline: 15 May 2026)
- Artificial Intelligence: New Molecules, Therapeutic Targets and Discovery of New Drugs (Deadline: 30 June 2026)
- Computation-Driven Discovery of Modern Small-Molecule Therapeutics: From Enzyme Inhibition to Targeted Protein Degradation (Deadline: 20 September 2026)
